# Phase ll Study of HEC585 in Patients With IPF

> **NCT05060822** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 270 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** HEC585
- **DRUG:** Pirfenidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05060822
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-30
- **Primary completion:** 2025-07-16
- **Final completion:** 2026-12-11
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05060822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05060822, "Phase ll Study of HEC585 in Patients With IPF". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05060822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*